TRCT
RLMD icon

Tower Research Capital (TRC)’s Relmada Therapeutics RLMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8K Buy
+6,186
New +$43.2K ﹤0.01% 2863
2025
Q4 		– Sell
-1,581
Closed -$3.18K – 5511
2025
Q3 		$3.18K Sell
1,581
-4,608
-74% -$4.42K ﹤0.01% 4538
2025
Q2 		$3.71K Buy
+6,189
New +$3.18K ﹤0.01% 4443
2025
Q1 		– Sell
-760
Closed -$396 – 5685
2024
Q4 		$396 Buy
+760
New +$1.85K ﹤0.01% 5288
2024
Q3 		– Sell
-2,754
Closed -$8.26K – 5935
2024
Q2 		$8.26K Sell
2,754
-7,002
-72% -$25.3K ﹤0.01% 4372
2024
Q1 		$45.4K Buy
9,756
+7,307
+298% +$35.2K ﹤0.01% 2350
2023
Q4 		$10.1K Buy
2,449
+739
+43% +$2.19K ﹤0.01% 4288
2023
Q3 		$5.13K Sell
1,710
-3,107
-65% -$9.23K ﹤0.01% 4756
2023
Q2 		$11.8K Buy
4,817
+198
+4% +$547 ﹤0.01% 3924
2023
Q1 		$10K Sell
4,619
-19,422
-81% -$67K ﹤0.01% 4400
2022
Q4 		$84K Buy
24,041
+23,189
+2,722% +$204K ﹤0.01% 1968
2022
Q3 		$32K Sell
852
-617
-42% -$17.1K ﹤0.01% 3556
2022
Q2 		$28K Buy
1,469
+1,261
+606% +$27.5K ﹤0.01% 3453
2022
Q1 		$6K Sell
208
-1,019
-83% -$21.1K ﹤0.01% 4917
2021
Q4 		$28K Buy
1,227
+546
+80% +$12.1K ﹤0.01% 3310
2021
Q3 		$18K Sell
681
-360
-35% -$9.64K ﹤0.01% 3834
2021
Q2 		$33K Sell
1,041
-757
-42% -$26.3K ﹤0.01% 3397
2021
Q1 		$63K Buy
1,798
+620
+53% +$21.7K ﹤0.01% 2933
2020
Q4 		$37K Sell
1,178
-11,104
-90% -$382K ﹤0.01% 3397
2020
Q3 		$462K Buy
12,282
+11,381
+1,263% +$440K 0.01% 1769
2020
Q2 		$40K Buy
+901
New +$38.1K ﹤0.01% 3235
2020
Q1 		– Sell
-2,143
Closed -$84K – 3763
2019
Q4 		$84K Buy
+2,143
New +$65.1K 0.01% 1043

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s RLMD Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 6,186 shares worth $42.8K. The stake represents ﹤0.01% of the portfolio and ranks #2863 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in RLMD as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in RLMD in Q4 2019 and has held it in 22 quarters since. The position peaked at $462K in Q3 2020. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Tower Research Capital (TRC) held 6,186 shares of Relmada Therapeutics worth $42.8K as of Q2 2026.
  • Relmada Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2863 holding.
  • Tower Research Capital (TRC) first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Relmada Therapeutics position peaked at $462K in Q3 2020.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.